Overview

Open-label, Multicenter, Extension Study to Evaluate Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Status:
Active, not recruiting
Trial end date:
2022-11-04
Target enrollment:
Participant gender:
Summary
This study is an open-label, single arm, multicenter, long-term safety and tolerability extension study for CSU patients who completed CLOU064A2201 or other preceding studies with LOU064
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals